中山专业肛肠科中山血便什么病,中山大便出血会是什么原因,中山肛医院,中山便血治疗得多少钱,中山肛瘘检查哪里好,中山大便擦屁屁纸上有点血,中山男人便血的原因有哪些

BEIJING, Aug. 25 (Xinhua) -- China pledged on Thursday to make more efforts to aid people living in the drought-stricken Horn of Africa in collaboration with the International Committee for the Red Cross (ICRC)."We noticed that the ICRC launched an appeal regarding the situation in the Horn of Africa. The Red Cross Society of China (RCSC) has decided to donate 4 million yuan (about 623,000 U.S. dollars) to the ICRC for its humanitarian aid in the region," said Hua Jianmin, president of the RCSC, while meeting with visiting ICRC President Jakob Kellenberger in Beijing on Thursday.Earlier this month, the RCSC donated 8 million yuan (1.25 million dollars) to famine-plagued countries in the Horn of Africa to be used for emergency humanitarian aid.A donation of 2 million yuan was sent to Kenya through the country's Red Cross organization, while another 2 million went to Ethiopia. The other 4 million yuan was donated to other countries in the region.The Chinese government has decided to provide a total of 90 million yuan (14 million dollars) in emergency food assistance to countries in the Horn of Africa."The Red Cross Society of China is willing to work together with the International Committee for the Red Cross to meet the needs of those who have been affected (by the droughts)," Hua said.Some 12.4 million people in Kenya, Ethiopia, Somalia and other countries in the region are in dire need of food due to a serious drought, the worst to hit the region since the 1980s.

LOS ANGELES, June 8 (Xinhua) -- NASA's Mars Exploration Rover Opportunity is heading toward "Spirit Point" on the rim of a large crater, a long-term destination that the rover has been trying to reach for nearly three years, the Jet Propulsion Laboratory (JPL) announced on Wednesday.Opportunity has moved toward the crater, Endeavour, since climbing out of Victoria crater in August 2008.Having driven 11 miles (18 kilometers), the rover has about two miles (about three kilometers) to go before reaching the rim of Endeavour, said JPL in Pasadena, Los Angeles.Rover team members last week selected "Spirit Point" as the informal name for the site on the rim where Opportunity will arrive at Endeavour crater. The choice commemorates Opportunity's rover twin, Spirit, which has ended communication and finished its mission."Spirit achieved far more than we ever could have hoped when we designed her," said Steve Squyres of Cornell University, Ithaca, New York, principal investigator for the rovers. "This name will be a reminder that we need to keep pushing as hard as we can to make new discoveries with Opportunity. The exploration of Spirit Point is the next major goal for us to strive for."Endeavour offers the setting for plenty of productive work by Opportunity. The crater is 14 miles (22 kilometers) in diameter -- more than 20 times wider than Victoria crater, which Opportunity examined for two years. Orbital observations indicate that the ridges along its western rim expose rock outcrops older than any Opportunity has seen so far. Spirit Point is at the southern tip of one of those ridges, "Cape York," on the western side of Endeavour.Opportunity and Spirit completed their three-month prime missions on Mars in April 2004. Both rovers continued for years of bonus, extended missions. Both have made important discoveries about wet environments on ancient Mars that may have been favorable for supporting microbial life.NASA's JPL, a division of the California Institute of Technology in Pasadena, manages the Mars Exploration Rover Project for the NASA Science Mission Directorate, Washington.

BEIJING, Aug. 15 (Xinhua) -- Scientists in a lab with Daya Bay Nuclear Power Station in southern Guangdong Province have found neutrino through two detecting instruments, which is likely to provide clues to solving the mystery of why there is more matter than antimatter in the universe.The Institute of High Energy Physics with the Chinese Academy of Sciences on Monday announced the breakthrough that was achieved by more than 250 researchers from six countries and regions.The two neutrino detectors are installed underground 360 meters away from the nuclear plant at a depth of 100 meters.Scientists believe that matter and antimatter were created in equal amounts during the Big Bang, but the disappearance of antimatter remains a mystery.Neutrino is an elementary particle that is able to pass through ordinary matter almost unaffected, which makes it extremely difficult to detect.Located in Shenzhen, a city neighboring Hong Kong, the Daya Bay Nuclear Power Station commenced operation in 1993.Scientists from the Chinese Academy of Sciences and the U.S.-based Brookhaven National Laboratory and the Lawrence Berkeley National Laboratory started the underground neutrino experiment in 2006.Kam-Biu Luk, spokesman for the laboratory, said that the results of the experiment would further shed light on the evolution of basic matter after the Big Bang.The neutrino experiment in the Daya Bay is one of the largest cooperation projects with regards to basic research between China and the United States.Among the participants of the experiment are Russia, Czech Republic, and China's Hong Kong and Taiwan regions.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, June 20 (Xinhuanet) -- American Cancer Society discloses that higher education appears to be a game changer when it comes to cancer, according to foreign media reports on Sunday. The research indicates that the gap is widening in cancer death rates between college graduates and those who only went to high school .Cancer death rates for those who didn’t finish high school are almost three times higher than those of college graduates. The gap was especially wide for lung cancer, but it was also palpably large for breast, colon, and prostate cancer. For lung cancer, the death rate was five times higher among the least educated Americans than the most educated.Ahmedin Jemal, ACS Vice President of Surveillance Research, said that higher smoking and obesity rates among lower-income Americans combined with less access to medical services mainly expounds the disparity.Researchers concluded that bridging the education-socioeconomic gap would have prevented about 60,000 premature cancer deaths in 2007 alone in people in the 25-64 age group.